📈 Jumpstart Signal Watchlist — September 17, 2026

🏢 What they do: Trivago operates an online hotel metasearch platform that lets travelers search, compare, and find hotel accommodations and rates from online travel agencies, booking sites, and hotels.
- 🎯 At/above 3yr high $6.69 (current $6.69) · ⏳ SMA200 $3.78 (current price $6.69 is above) · 💰 Market Cap $2.4B
- TRVG shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 144% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0); PEG ratio 1.40 (<1.5).
⏰ Entry (E): 7/20
- 🔔 Strong above EMA21 (16.4%)
- 🔔 Strong above EMA50 (23.6%)
- 🔔 High-vol breakout (rank=1.90x, quality=0.91)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×2).
✅ trivago (TRVG) Stock Sees Fair Value Lift After Earnings Beat And Raised Guidance — Finance Yahoo.
🤖 This article says trivago beat earnings and raised guidance, and that analysts lifted fair value estimates. Those are direct fundamental catalysts that are generally positive for the stock.
✅ Trivago N.V. ADS (NASDAQ:TRVG) Stock Rating Upgraded by Zacks Research — MarketBeat.
🤖 Zacks Research upgraded TRVG from hold to strong buy, which is a constructive analyst-action catalyst. The article also notes other analysts raised price targets, reinforcing a positive tone.
⚪️ Trivago N.V. ADS (NASDAQ:TRVG) Given Average Rating of "Hold" by Brokerages — MarketBeat.
🤖 The article mainly reiterates a consensus hold rating and summarizes analyst coverage, with no major new company catalyst. It is informational rather than clearly bullish or bearish.
⚪️ Trivago N.V. ADS (NASDAQ:TRVG) Short Interest Up 284.4% in August — MarketBeat.
🤖 This reports a sharp rise in short interest and mentions an insider sale, but it does not present a new operating catalyst or material corporate event. Per the rules, the ownership/flow items are treated as neutral.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: MISTRAS Group provides technology-enabled industrial asset integrity and asset protection solutions, including non-destructive testing, inspection, monitoring, and engineering services. It also offers related testing products, systems, and software for critical infrastructure and industrial assets.
- 🎯 Current $19.84 is 1% below 3yr high $19.98 · ⏳ SMA200 $15.98 (current price $19.84 is above) · 💰 Market Cap $632M
- MG shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 130% (>20%); Low LT D/E 0.72 (<1.0); PEG ratio 0.18 (<1.5).
⏰ Entry (E): 3/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×3; showing 4 of 5).
✅ Mistras Group Opens Five New US Locations — Investing.com.
🤖 MISTRAS opened five new U.S. field-service locations to expand its industrial asset-integrity and laboratory-testing footprint. The expansion could support future growth and customer coverage.
✅ MISTRAS Group Accelerates AI and Digital Innovation Strategy — Yahoo Finance.
🤖 The company announced an accelerated AI strategy and appointed an executive director of artificial intelligence to develop scalable enterprise capabilities. The initiative is potentially positive because it aims to turn MISTRAS’s industry data and digital assets into new operational and commercial value.
⚪️ Mistras Group (NYSE:MG) Reaches New 1-Year High - Time to Buy? — MarketBeat.
🤖 The article reports that MG reached a new 52-week high and reviews analyst ratings, including a recent downgrade to Hold and a consensus Hold rating with a $19.00 target. The mixed analyst backdrop makes the article neutral despite the price-strength report.
⚪️ BlackRock Inc. Invests $20.37 Million in Mistras Group Inc $MG — MarketBeat.
🤖 The article describes BlackRock’s second-quarter 13F position in MG, a routine backward-looking institutional ownership disclosure. Under the stated classification rule, this is neutral rather than a directional catalyst.
🍭 Bonus (B): 0/10 — Engineering Services

🏢 What they do: Magnite is an advertising technology company that provides a sell-side platform for digital advertising. Its software helps publishers and media owners manage and monetize ad inventory across channels like connected TV, video, mobile, and desktop, while also connecting them with advertisers and agencies.
- 🎯 Current $25.63 is 3% below 3yr high $26.52 · ⏳ SMA200 $16.36 (current price $25.63 is above) · 💰 Market Cap $3.7B
- MGNI shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 Base breakout (range: 8.7%); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 62% (>20%); ROE 18% (>15%); Low LT D/E 0.37 (<1.0).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA21 (8.0%)
- 🔔 Strong above EMA50 (15.4%)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Magnite Gets Price-Target Hikes After Google Ad-Tech Ruling — Why Analysts See A Win For Independent Ad Tech — Yahoo Finance.
🤖 Analysts raised price targets on MGNI after a favorable Google ad-tech ruling, with StoneX lifting its target to $43 and Craig-Hallum also boosting its target. The article frames the ruling as a meaningful win for independent ad tech, which is constructive for Magnite's outlook.
✅ Magnite stock price target raised to $43 by StoneX on remedy ruling — Investing.com.
🤖 StoneX raised its price target on Magnite to $43 while keeping a Buy rating, citing the remedy ruling as a catalyst. The piece also notes Magnite's recent earnings beat and higher full-year outlook, both positive signals for the stock.
✅ Magnite Jumps 5% as Craig-Hallum Lifts Target to $32 on Google Auction Remedies; PubMatic Rises 6%, Trade Desk Barely Budges — Yahoo Finance.
🤖 The article says Magnite surged after Google antitrust remedies favored interoperability and independent ad tech. That kind of regulatory development can improve Magnite's competitive position and is supportive for shares.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $58.49 is 1% below 3yr high $59.13 · ⏳ SMA200 $48.09 (current price $58.49 is above) · 💰 Market Cap $14.6B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 2/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 6/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×3 ❌×2; showing 4 of 5).
✅ Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B — Yahoo Finance.
🤖 Exelixis reported that Cabozantinib has surpassed a $3 billion annualized run rate and said it is preparing for a zanzalintinib launch while pursuing selective oncology deals. These updates support the company’s growth outlook, though the launch remains subject to regulatory approval.
✅ Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts — Yahoo Finance.
🤖 The company highlighted rising CABOMETYX market share, a potential neuroendocrine-tumor opportunity, zanzalintinib development programs, and an estimated $5 billion addressable market. Continued investment alongside an active $750 million buyback provides additional supportive signals for shareholders.
❌ Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval? — Yahoo Finance.
🤖 The FDA extended its review of zanzalintinib by three months to March 3, 2027 after requesting updated safety and efficacy information. The delay postpones regulatory clarity and the potential commercial launch, although it does not represent a rejection.
❌ Exelixis stock falls as FDA extends zanzalintinib review — Investing.com.
🤖 Shares fell 3.5% in premarket trading after the FDA extended the zanzalintinib review by three months following submission of updated safety and efficacy data. The revised March 3, 2027 action date delays a potentially important product catalyst.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $35.53 is 2% below 3yr high $36.37 · ⏳ SMA200 $25.74 (current price $35.53 is above) · 💰 Market Cap $4.5B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (8.4% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Concentra Group Holdings Parent (CON) Beats Again And Expands In Florida, Is The Stock Still Undervalued? — Yahoo Finance.
🤖 The article says Concentra drew attention after another earnings beat and the opening of a new occupational health center in Daytona Beach, Florida. It also notes the stock remains below a widely followed fair value estimate, which supports a constructive view.
✅ Concentra Group Holdings Parent (NYSE:CON) Reaches New 52-Week High — MarketBeat.
🤖 The article reports CON hit a new 52-week high and cites strong prior earnings, higher analyst price targets, and ongoing positive analyst sentiment. The move reflects improving investor expectations and price momentum.
⚪️ Concentra Appoints Tanner Newton Chief Financial Officer — Business Wire.
🤖 Concentra announced an executive leadership change, naming Tanner Newton as CFO effective Nov. 1, 2026. This is company-specific news, but it is an organizational announcement rather than a direct operational or financial catalyst.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: HealthStream provides software and online services for healthcare organizations to manage workforce learning, training, credentialing, competency, and scheduling. Its tools help hospitals and other care providers develop staff and support compliance and performance management.
- 🎯 Current $29.19 is 14% below 3yr high $34.07 · ⏳ SMA200 $24.27 (current price $29.19 is above) · 💰 Market Cap $854M
- HSTM shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (9.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 28% (>20%); Low LT D/E 0.08 (<1.0); PEG ratio 1.46 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 53 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ HealthStream Completes $40 Million Private Placement of Its Common Stock — Business Wire.
🤖 HealthStream completed a private placement that raised approximately $40 million at $29.50 per share, providing additional capital and bringing in a strategic investor. The CEO’s concurrent sale of existing shares is a neutral ownership transaction, but the company’s capital raise is modestly positive.
✅ HealthStream Defines a New Enterprise Category Alongside the EHR and ERP, the Enterprise Clinical Workforce Platform (ECWP) — Business Wire.
🤖 HealthStream introduced the Enterprise Clinical Workforce Platform category, positioning its products as an integrated clinical workforce technology platform. The announcement may support the company’s growth narrative and market differentiation.
❌ HealthStream (NASDAQ:HSTM) Downgraded by Wall Street Zen to Hold — MarketBeat.
🤖 Wall Street Zen downgraded HealthStream from Buy to Hold, adding pressure to the stock’s near-term outlook. The article also cites prior earnings that exceeded expectations, which partially offsets the negative rating signal.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Red Violet, Inc. provides identity intelligence software and data solutions for identity verification, fraud detection and prevention, risk mitigation, investigations, due diligence, customer acquisition, and asset recovery. Its products include idiCORE and FOREWARN.
- 🎯 Current $77.12 is 0% below 3yr high $77.52 · ⏳ SMA200 $53.45 (current price $77.12 is above) · 💰 Market Cap $1.1B
- RDVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 89% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0); PEG ratio 0.77 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (11.2%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 61 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Raymond James initiates Red Violet stock coverage with outperform rating — Investing.com.
🤖 Raymond James initiated coverage with an Outperform rating and a $90 price target, above the stock’s recent trading level. The article also cited Red Violet’s stronger-than-expected second-quarter results, including 23% revenue growth and record adjusted EBITDA, cash flow, and customer additions.
✅ Red Violet (NASDAQ:RDVT) Hits New 12-Month High — MarketBeat.
🤖 Red Violet reached a new 52-week high after reporting adjusted EPS and revenue above consensus expectations. The article highlighted a Moderate Buy analyst consensus and Needham’s $90 price target, although it also noted a Weiss Ratings downgrade to Hold.
✅ Red Violet Inc stock hits all-time high at 77.5 USD — Investing.com.
🤖 The stock reached an all-time high, supported by better-than-expected second-quarter earnings, 23% year-over-year revenue growth, and record adjusted EBITDA, cash flow, and customer additions. Needham’s Buy rating and $90 target provided additional positive analyst support.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)